Facebook
Twitter
LinkedIn
ForwardTimothy Fenske
Dr. Fenske is currently a Professor of Medicine at the Medical College of Wisconsin, where he has practiced since finishing training in 2005. His clinical and research efforts are focused on improving outcomes for patients with all types of lymphoma. This includes clinical and translational science focused on novel chemotherapy, immunotherapy, targeted therapies and cellular/ transplant therapies. He attended medical school at the the University of Wisconsin-Madison, also completing a master's in cell and molecular biology there. He then stayed at UW Madison for internal medicine residency, followed by hematology/ oncology fellowship at Washington University / Barnes-Jewish Hospital in St. Louis. He has over 150 publications including invited reviews and book chapters. He is currently a member of the NCI Lymphoma Steering Committee, and former co-chair of the CIBMTR Lymphoma Working Committee. He is currently serving as national chair or co-chair on two nationwide NCTN trials in lymphoma.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Adaptive BiotechnologiesTopic:MRDDate added:08/21/2023Relationship end date:04/01/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AstrazenecaTopic:CLLDate added:08/21/2023Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BeigeneTopic:CLL and MCLDate added:08/21/2023Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Kite (Gilead)Topic:CAR T therapyDate added:08/21/2023Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Lilly/LoxoTopic:BTK inhibitorsDate added:08/21/2023Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:MorphoSysTopic:DLBCLDate added:08/21/2023Relationship end date:01/30/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AbbVieTopic:ibrutinibDate added:08/21/2023Relationship end date:10/31/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:SanofiTopic:BMTDate added:08/21/2023Relationship end date:02/01/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:TG TherapeuticsTopic:PI3K inhibitorsDate added:08/21/2023Relationship end date:03/30/2022